Multi-client Studies and Market Research

An International Comparison of Evolving Requirements

Developing clinical trial data necessary for reimbursement dossiers is a costly process, and the information needs of regulators, reimbursement authorities, and payers are often very different. This leaves pharmaceutical companies unclear on what are the best types of data to develop in order to secure reimbursement across multiple markets. This study explores the types of data payers are willing to consider to approve and set reimbursement levels for a given drug.

• Download Brochure
• Download Table of Contents
• Buy Now

A Country Specific Analysis

Medical device and diagnostic launches are highly fragmented across — and often within — countries. Market access and reimbursement issues in this area are complex and often driven by a mix of governments, insurance companies, and major hospital systems, and successful sales often depend on physician relationships. This study provides a clear view of the key issues for regulatory stakeholders, insurers and secondary-care decision makers in Canada, Australia, Japan, the EU top 5, and the United States.

• Download Brochure
• Download Table of Contents
• Buy Now

Hospital stays, procedures, and secondary-care pharmaceuticals increasingly weigh on total healthcare budgets.

Based on primary research with regulatory stakeholders, secondary-care decision makers and influencers, and hospital and retail pharmacists, this study provides a detailed view of the current state of the hospital drug market in 12 European countries: Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

• Download Brochure
• Download Table of Contents
• Buy Now

Best Practices for Successful Market Access of New Pharmaceuticals

Mounting healthcare costs and growing economic pressure have payers around the globe challenged to balance budgets, while ensuring quality healthcare for their patient population. While commercial and price agreements have been a popular way to control payer costs for innovative drugs they are not the only option. This study explores the types of payer-industry strategic partnerships that are emerging, as well as the best practices for establishing such partnerships.

• Download Brochure
• Download Table of Contents
• Buy Now

How will Germany's Healthcare Reform Impact Global Pricing and Reimbursement Strategies

With prices ranking among the highest in the world, the German pharmaceutical market is seen as a critical priority for medicine manufacturers. However, the restructuring of the German pricing and reimbursement system has brought considerable challenges for industry players operating in the country. This study offers a detailed look at German healthcare reform and what it really means for the global pharmaceutical industry.

• Download Brochure
• Download Table of Contents
• Buy Now

A Global Analysis of Shifting Patterns

In today’s complex pricing and reimbursement landscape, the sequence in which a drug is launched has a significant impact on its overall success. Pharmaceutical companies need to understand not only the forces at play within each market, but also the cross-market dynamics that can impact the success of a launch.

This study explores how cross-market dynamics impact specific product launch sequencing strategies within 20 of the world’s largest markets and provides the critical insight needed to develop an informed launch sequence strategy that maximizes revenue.

• Download Brochure
• Download Table of Contents
• Buy Now

Market Access Strategies in the World's Fastest Growing Markets

Emerging markets are increasingly attractive to pharmaceutical companies, presenting strong opportunities for expansion and diversification; however, the challenging regulatory landscapes can pose investment risks. Based on detailed interviews with regulatory authorities, this study examines the role of public and private healthcare insurers, and pricing and reimbursement policies for drugs developed in BRIC-MT countries.

• Download Brochure
• Download Table of Contents
• Buy Now

Attaching Value to Treatments for Rare Diseases

The risks of developing new medicines are increasing, as pharmaceutical and biotech companies face stringent pricing and reimbursement conditions that do not always cover their research and development investments. Pharmaceutical and biotech companies are increasingly focusing on rarer "orphan" diseases, where there are fewer competitors and significant regulatory investment incentives. This study explores the regulatory incentives, emerging competition, and the value of orphan drugs for Australia, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States, and enables pharmaceutical and biotech companies to define the market opportunities presented by orphan drugs.

• Download Brochure
• Download Table of Contents
• Buy Now

The biosimilars market is continually evolving and changing. Pharmaceutical companies need to understand how doctors and pharmacies react to these changes.

This study analyzes the biosimiars market for Belgium, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, the United Kingdom, and the United States.

• Download Table of Contents
• Buy Now

Implications for Market Access Strategies

This study provides a detailed analysis of what the new pharmacovigilance legislation means in terms of PAES/PASS, and assesses how this framework is likely to evolve—taking into account growing activity at the payer/regulatory interface.

• Download Brochure
• Download a Sample Analysis

What's Really Behind Drug Price Changes?

A comprehensive pricing analysis that harnesses our unique combination of pharmaceutical pricing databanks, industry expertise, and macroeconomic forecasts of key market drivers such as inflation, costs, and exchange rates.

With information across all of the countries in our POLI database, this update study will help you understand the drivers behind drug price changes by country so you can develop more informed budgets and go-to-market strategies.

• Download Brochure
• Download a Sample Analysis

Best Practices for Successful Market Access of New Pharmaceuticals

This study explores the types of payer-industry strategic partnerships that are emerging, the best practices for establishing such partnerships, and the critical success factors pharma companies need to consider in the developing world.

• Download Brochure
• Download a Sample Analysis

An International Comparison of Evolving Requirements

Developing clinical trial data necessary for reimbursement dossiers is a costly process, and the information needs of regulators, reimbursement authorities, and payers are often very different. This leaves pharmaceutical companies unclear on what are the best types of data to develop in order to secure reimbursement across multiple markets. This study explores the types of data payers are willing to consider to approve and set reimbursement levels for a given drug.

• Download Brochure
• Purchase Online Now

A Country Specific Analysis

This study provides a clear view of the market access and reimbursement landscapes for medical devices and diagnostics in Canada, Australia, Japan, the EU top 5 and the United States.

• Download Brochure
• Purchase Online Now

A 2011 Survey of the European Hospital Drug Market

A detailed view of the current state of the hospital drug market in 12 European countries: Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

• Download Brochure
• Purchase Online Now

Best Practices for Successful Market Access of New Pharmaceuticals

Mounting healthcare costs and growing economic pressure have payers around the globe challenged to balance budgets, while ensuring quality healthcare for their patient population. While commercial and price agreements have been a popular way to control payer costs for innovative drugs they are not the only option. This study explores the types of payer-industry strategic partnerships that are emerging, as well as the best practices for establishing such partnerships.

• Download Brochure
• Purchase Online Now

How will Germany's Healthcare Reform Impact Global Pricing and Reimbursement Strategies

With prices ranking among the highest in the world, the German pharmaceutical market is seen as a critical priority for medicine manufacturers. However, the restructuring of the German pricing and reimbursement system has brought considerable challenges for industry players operating in the country. This study offers a detailed look at German healthcare reform and what it really means for the global pharmaceutical industry.

• Download Brochure
• Purchase Online Now

A Global Analysis of Shifting Patterns

In today’s complex pricing and reimbursement landscape, the sequence in which a drug is launched has a significant impact on its overall success. Pharmaceutical companies need to understand not only the forces at play within each market, but also the cross-market dynamics that can impact the success of a launch.

This study explores how cross-market dynamics impact specific product launch sequencing strategies within 20 of the world’s largest markets and provides the critical insight needed to develop an informed launch sequence strategy that maximizes revenue.

• Download Brochure
• Purchase Online Now

Understanding Critical Drivers and Their Impact in 36 Key Markets

This study provides a comprehensive view of global healthcare markets, their key drivers, and the market impact of key events. Featuring summary forecasts, primary research, a detailed report, and a workshop, the study gives you the tools you need to quantify future market growth.

• Download Brochure

Market Access Strategies in the World's Fastest Growing Markets

Emerging markets are increasingly attractive to pharmaceutical companies, presenting strong opportunities for expansion and diversification; however, the challenging regulatory landscapes can pose investment risks. Based on detailed interviews with regulatory authorities, this study examines the role of public and private healthcare insurers, and pricing and reimbursement policies for drugs developed in BRIC-MT countries.

• Download Brochure
• Purchase Online Now

Business Opportunities in the Private Healthcare Sector

We explore the alliances that pharma companies and private healthcare insurers could form to widen the range of products covered, attract new clients and boost sales of products lacking government funding.

• Download Brochure

Attaching Value to Treatments for Rare Diseases

The risks of developing new medicines are increasing, as pharmaceutical and biotech companies face stringent pricing and reimbursement conditions that do not always cover their research and development investments. Pharmaceutical and biotech companies are increasingly focusing on rarer “orphan” diseases, where there are fewer competitors and significant regulatory investment incentives. This study explores the regulatory incentives, emerging competition, and the value of orphan drugs for Australia, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States, and enables pharmaceutical and biotech companies to define the market opportunities presented by orphan drugs.

• Download Brochure
• Purchase Online Now

Biosimilars in Europe and the United States

The biosimilars market is continually evolving and changing. Pharmaceutical companies need to understand how doctors and pharmacies react to these changes.

This study analyzes the biosimiars market for Belgium, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, the United Kingdom, and the United States.

• Buy Now

An Alternative Approach to Pricing Negotiations

This study provides pharmaceutical companies with a comprehensive analysis of the risk-sharing agreement process and highlights best practices for negotiating with payers , The study will assist pharmaceutical companies in developing their market opportunities by using this negotiation strategy. This report includes analyses of nine countries: Australia, Canada, France, Germany, Italy, New Zealand, Spain, the United Kingdom, and the United States.

• Download Brochure

Insight into a New Medical Model

This study is designed to assist pharmaceutical, biotechnology, and diagnostic companies in developing their market opportunities in theranostics.

Managing Relationships in 12 European Markets

This study is designed for healthcare professionals seeking to develop strategies for distribution of drugs throughout pharmacies in Europe. The report includes analyses of 12 European countries: Belgium, France, Germany, Greece, Hungary,Italy, the Netherlands, Poland, Portugal, Spain, Sweden, and the United Kingdom.

A Survey of the European Hospital Drug Market

This study offers a comprehensive survey of the European hospital drug market, allowing healthcare industry professionals to develop strategies for distribution of drugs throughout hospitals in Europe. The report includes in-depth analyses of the hospital drug market in 12 European countries: Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

Successfully Developing Pharmaceuticals in 15 European Markets

The report includes analyses of pricing and reimbursement systems in 19 European countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Netherlands, Poland, Portugal, Republic Czech, Spain, Sweden, Switzerland, and the United Kingdom.